(AP) - DRUG DO-OVER: Johnson & Johnson is taking a second shot at getting U.S. approval to market anticlotting drug Xarelto for two additional uses.
THE HISTORY: This summer, the Food and Drug Administration rejected one of those applications and J&J withdrew the other. J&J has now submitted new data from a huge Xarelto study concluded last year.
THE MARKET: Xarelto is approved for reducing blood clot risk after knee or hip replacement surgery and lowering stroke risk in patients with an irregular heartbeat. It competes with one drug in a new generation of blood thinners, Pradaxa. Another, Eliquis, could be approved.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Check out the most expensive home for sale in the U.S. (Video)
J.K. Rowling scribbled notes and drawings in a first-edition copy.
Something unusual: Acupuncture for ailing sea turtles. (Photos)
Seth MacFarlane makes his decision on hosting next year's Oscars.